Foti A G, Herschman H, Cooper J F
Cancer Res. 1975 Sep;35(9):2446-52.
A solid-phase technique for radioimmunoassay of human prostatic acid phosphatase (EC 3.1.3.2) is described. Human prostatic acid phosphatase was purified from prostatic fluid. Monospecific antisera to the purified acid phosphatase were produced in rabbits. Disposable polypropylene tubes were coated with antiserum and used for radioimmunoassay with 125I-acid phosphatase. The nonspecific binding was minimized by saturating the binding sites of the tubes with bovine serum albumin. The working range of the technique was 1 to 30 ng of antigen. The solid-phase radioimmunoassay is rapid, sensitive, and efficient. In preliminary clinical trials it was shown that (a) patients with advanced prostatic cancer had elevated prostatic acid phosphatase levels by both enzymatic assay and radioimmunoassay assays, and (b) patients with other cancers were in the normal range for prostatic acid phosphatase.
本文描述了一种用于人前列腺酸性磷酸酶（EC 3.1.3.2）放射免疫测定的固相技术。人前列腺酸性磷酸酶从前列腺液中纯化得到。用纯化的酸性磷酸酶在兔体内产生单特异性抗血清。一次性聚丙烯管包被抗血清后，用于与125I-酸性磷酸酶进行放射免疫测定。通过用牛血清白蛋白饱和管的结合位点，使非特异性结合降至最低。该技术的工作范围为1至30 ng抗原。固相放射免疫测定快速、灵敏且高效。初步临床试验表明：（a）晚期前列腺癌患者通过酶促测定和放射免疫测定，其前列腺酸性磷酸酶水平均升高；（b）其他癌症患者的前列腺酸性磷酸酶水平在正常范围内。
